Anabolic-Androgenic Steroid Therapy in the treatment of chronic diseases.
J Clin Endocrinol Metab. 86: 5108-5117Dunn J.F. Nisula B.C. Rodbard D.Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma.
J Clin Endocrinol Metab. 53: 58-68Bhasin S. Cunningham G.R. Hayes F.J. et al.Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.
J Clin Endocrinol Metab. 95: 2536-2559Male hypogonadism.
Lancet. : 5-11Melmed S. Polonsky K.S. Reed L.P. et al.Williams textbook of endocrinology.
Elsevier Health Sciences, White C. MJ F.-B. NM M. et al.The pharmacokinetics of intravenous testosterone in elderly men with coronary artery disease.
J Clin Pharmacol. 38: 792-797Testosterone metabolism,dose-response relationships and receptor polymorphisms:selected pharmacologi.toxicological considerations on benefits versus the risks of testosterone therpay in men.
Aging Male. 6: 230-256Bhasin S.W.L. Casaburi R. Singh A.B. et al.Testosterone doe-response relationships in healthy young men.
Am J Physiol Endocrinol Metab. 281: E1172-E1181Non-genomic actions of sex steroid hormones.
Eur J Endocrtinology. 148: 281-292Papakonstanti E.A.K.M. Castanas E. Stounaras C.A rapid,nongenomic,signnaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors.
Mol Endocrinol. 17: 870-881The roles of androgen receptors and androgen-binding proteions in non genomic androgen action.
Mol Endocrinol. 16: 2181-2187Brambilla D.J. O'Donnell A.B. Matsumoto A.M. et al.Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men.
Clin Endocrinol (Oxf). 67: 853-862Brambilla D.J. Matsumoto A.M. Araujo A.B. et al.The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men.
J Clin Endocrinol Metab. 94: 907-913Gonzalez-Sales M. Barriere O. Tremblay P.O. et al.Modeling Testosterone Circadian Rhythm in Hypogonadal Males: Effect of Age and Circannual Variations.
AAPS J. 18: 217-227Welliver Jr., R.C. Wiser H.J. Brannigan R.E. et al.Validity of midday total testosterone levels in older men with erectile dysfunction.
J Urol. 192: 165-169Testosterone replacement therapy faces FDA scrutiny.
JAMA. 313: 563-564Caronia L.M. Dwyer A.A. Hayden D. et al.Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism.
Clin Endocrinol (Oxf). 78: 291-296Lehtihet M. Arver S. Bartuseviciene I. et al.S-testosterone decrease after a mixed meal in healthy men independent of SHBG and gonadotrophin levels.
Andrologia. 44: 405-410Mulhall J.P. Trost L.W. Brannigan R.E. et al.Evaluation and management of testosterone deficiency: AUA guideline.
J Urol. 200: 423-432Locke J.A. Flannigan R. Gunther O.P. et al.Testosterone therapy: Prescribing and monitoring patterns of practice in British Columbia.
Can Urol Assoc J. 15: E110-E117Grabner M. Hepp Z. Raval A. et al.Topical testosterone therapy adherence and outcomes among men with primary or secondary hypogonadism.
J Sex Med. 15: 148-158Schoenfeld M.J. Shortridge E. Cui Z. et al.Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.
J Sex Med. 10: 1401-1409Donatucci C. Cui Z. Fang Y. et al.Long-term treatment patterns of testosterone replacement medications.
J Sex Med. 11: 2092-2099Sex, Energy, Well-Being and Low Testosterone: An Exploratory Survey of U.S. Men's Experiences on Prescription Testosterone.
Int J Environ Res Public Health. 16https://doi.org/10.3390/ijerph16183261Gilbert K. Cimmino C.B. Beebe L.C. et al.Gaps in patient knowledge about risks and benefits of testosterone replacement therapy.
Urology. 103: 27-33Dwyer A.A. Tiemensma J. Quinton R. et al.Adherence to treatment in men with hypogonadotrophic hypogonadism.
Clin Endocrinol (Oxf). 86: 377-383Shoskes J.J. Wilson M.K. Spinner M.L.Pharmacology of testosterone replacement therapy preparations.
Transl Androl Urol. 5: 834-843Swerdloff R.S. Wang C. Cunningham G. et al.Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
J Clin Endocrinol Metab. 85: 4500-4510Miller J. Britto M. Fitzpatrick S. et al.Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism.
Endocr Pract. 17: 574-583Transdermal delivery of testosterone.
Eur J Pharm Biopharm. 92: 42-48Review of testim gel.
Expert Opin Pharmacother. 7: 477-484Dobs A.S. McGettigan J. Norwood P. et al.A novel testosterone 2% gel for the treatment of hypogonadal males.
J Androl. 33: 601-607https://doi.org/10.2164/jandrol.111.014308Morgentaler A. McGettigan J. Xiang Q. et al.Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.
Int J Impot Res. 27: 41-45Dobs A.S. Meikle A.W. Arver S. et al.Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
J Clin Endocrinol Metab. 84: 3469-3478 ()Mattern C. Hoffmann C. Morley J.E. et al.Testosterone supplementation for hypogonadal men by the nasal route.
Aging Male. 11: 171-178https://doi.org/10.1080/13685530802351974Banks W.A. Morley J.E. Niehoff M.L. et al.Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone.
J Drug Target. 17: 91-97Rogol A.D. Tkachenko N. Bryson N.Natesto , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
Andrology. 4: 46-54Masterson T. Molina M. Ibrahim E. et al.Natesto effects on reproductive hormones and semen parameters: results from an ongoing single-center, investigator-initiated phase IV clinical trial.
Eur Urol Focus. 4: 333-335 ()Sclar D.A. Tartaglione T.A. Fine M.J.Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases.
Infect Agents Dis. 3: 266-273Nieschlag E. Mauss J. Coert A. et al.Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate.
Acta Endocrinol (Copenh). 79: 366-374Horst H.J. Holtje W.J. Dennis M. et al.Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man.
Klin Wochenschr. 54: 875-879Swerdloff R.S. Dudley R.E.A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men.
Ther Adv Urol. 12 ()Schurmeyer T. Wickings E.J. Freischem C.W. et al.Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men.
Acta Endocrinol (Copenh). 102: 456-462Bagchus W.M. Hust R. Maris F. et al.Important effect of food on the bioavailability of oral testosterone undecanoate.
Pharmacotherapy. 23: 319-325A Review of Testosterone Pellets in the Treatment of Hypogonadism.
Curr Sex Health Rep. 6: 265-269Pastuszak A.W. Mittakanti H. Liu J.S. et al.Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
J Androl. 33: 927-937Figueiredo M.G. Gagliano-Juca T. Basaria S.Testosterone Therapy with Subcutaneous Injections: A Safe, Practical and Reasonable Option.
J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgab772Spratt D.I. Stewart II, Savage C. et al.Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients.
J Clin Endocrinol Metab. 102: 2349-2355Rohayem J. Tüttelmann F. Nieschlag E. et al.Hypothalamisch bedingter hypogonadotroper Hypogonadismus.
in: Nieschlag E. Behre H.M. Kliesch S. Andrologie: grundlagen und Klinik der reproduktiven Gesundheit des Mannes. Springer, Berlin Heidelberg: 1-10Kaminetsky J.C. McCullough A. Hwang K. et al.A 52-week study of dose adjusted subcutaneous testosterone enanthate in oil self-administered via disposable auto-injector.
J Urol. 201: 587-594Pastuszak A.W. Hu Y. Freid J.D.Occurrence of pulmonary oil microembolism after testosterone undecanoate injection: a postmarketing safety analysis.
Sex Med. 8: 237-242
留言 (0)